These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20521114)

  • 1. Omega-3 fatty acids: a promising alternative treatment approach for patients with nonalcoholic fatty liver disease.
    Beyazit Y; Purnak T; Kekilli M
    Dig Dis Sci; 2010 Aug; 55(8):2422-3; author reply 2423. PubMed ID: 20521114
    [No Abstract]   [Full Text] [Related]  

  • 2. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease.
    Shapiro H; Tehilla M; Attal-Singer J; Bruck R; Luzzatti R; Singer P
    Clin Nutr; 2011 Feb; 30(1):6-19. PubMed ID: 20619513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.
    Cussons AJ; Watts GF; Mori TA; Stuckey BG
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3842-8. PubMed ID: 19622617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 polyunsaturated fatty acids: a specific liver drug for non-alcoholic fatty liver disease (NAFLD).
    Xin YN; Xuan SY; Zhang JH; Zheng MH; Guan HS
    Med Hypotheses; 2008 Nov; 71(5):820-1. PubMed ID: 18752901
    [No Abstract]   [Full Text] [Related]  

  • 5. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.
    Masterton GS; Plevris JN; Hayes PC
    Aliment Pharmacol Ther; 2010 Apr; 31(7):679-92. PubMed ID: 20415840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease.
    Li Y; Chen D
    J Hepatol; 2012 Aug; 57(2):468-9; author reply 469-70. PubMed ID: 22433603
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
    Zhu FS; Liu S; Chen XM; Huang ZG; Zhang DW
    World J Gastroenterol; 2008 Nov; 14(41):6395-400. PubMed ID: 19009658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor.
    Alwayn IP; Andersson C; Zauscher B; Gura K; Nosé V; Puder M
    Transplantation; 2005 Mar; 79(5):606-8. PubMed ID: 15753852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nitric oxide in the treatment of non-alcoholic fatty liver by omega-3 fatty acids.
    Beyazit Y; Purnak T; Kekilli M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):303-4. PubMed ID: 20636624
    [No Abstract]   [Full Text] [Related]  

  • 11. [Omega-3 fatty acids as an option in the treatment of NAFLD].
    Singer P
    MMW Fortschr Med; 2011 Oct; 153 Suppl 3():90-4. PubMed ID: 22184802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids.
    Bouzianas DG; Bouziana SD; Hatzitolios AI
    Nutr Rev; 2013 Nov; 71(11):753-71. PubMed ID: 24148001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease.
    Alwayn IP; Gura K; Nosé V; Zausche B; Javid P; Garza J; Verbesey J; Voss S; Ollero M; Andersson C; Bistrian B; Folkman J; Puder M
    Pediatr Res; 2005 Mar; 57(3):445-52. PubMed ID: 15659701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought.
    Adams LA; Lindor KD
    Indian J Gastroenterol; 2004; 23(4):127-8. PubMed ID: 15333965
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease.
    Paredes AH; Torres DM; Harrison SA
    Clin Liver Dis; 2012 May; 16(2):397-419. PubMed ID: 22541706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats.
    Marsman HA; Heger M; Kloek JJ; Nienhuis SL; ten Kate FJ; van Gulik TM
    Dig Liver Dis; 2011 Dec; 43(12):984-90. PubMed ID: 21840275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of diet and omega-3 fatty acids in NAFLD.
    Popescu LA; Vîrgolici B; Lixandru D; Miricescu D; Condruţ E; Timnea O; Ranetti AE; Militaru M; Mohora M; Zăgrean L
    Rom J Morphol Embryol; 2013; 54(3 Suppl):785-90. PubMed ID: 24322028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of nonalcoholic steatohepatitis: an evidence-based approach.
    Mahady SE; George J
    Clin Liver Dis; 2012 Aug; 16(3):631-45. PubMed ID: 22824485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver: role of inflammation and fatty acid nutrition.
    Byrne CD
    Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.